Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Myeloma: MAIA, COLUMBA, and CASSIOPEIA updates

Thierry Facon • 14 Jun 2019
EHA 2019
Multiple Myeloma Daratumumab Dexamethasone Lenalidomide Pomalidomide
CASSIOPEIA COLUMBA MAIA

Thierry Facon, MD, Lille University Hospital, Lille, France, gives us an update on the CASSIOPEIA study (NCT02541383), which evaluated daratumumab in transplant-eligible patients with previously untreated multiple myeloma. Speaking from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Dr Facon also gives us an update on other trials, such as MAIA (NCT02252172), and COLUMBA (NCT03277105).

More from Thierry Facon

3:23
Upcoming updates in multiple myeloma
Thierry Facon • 14 Jun 2019
AMG 420 BiTE for R/R multiple myeloma
Thierry Facon • 11 Dec 2018
Daratumumab plus Rd for newly diagnosed multiple myeloma (NDMM)
Thierry Facon • 11 Dec 2018
MAIA trial: addition of daratumumab to Rd in newly diagnosed transplant-ineligible MM
Thierry Facon • 6 Dec 2018

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals